BiotechTube
SMSbiotech

SMSbiotech

San Diego, United States· Est.
smsbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

SMSbiotech is a private, clinical-stage biotech founded in 2015 and based in San Diego, California. The company's core asset is its patented Small Mobile Stem (SMS) cell platform, which produces unique, scalable adult stem cells from human blood for systemic, off-the-shelf therapies. Its lead program for COPD has completed a Phase 1b trial showing early safety and efficacy signals, positioning the company to advance into U.S. Phase 2 development. SMSbiotech operates as a therapeutics company with in-house biomanufacturing capabilities but is currently pre-revenue.

Chronic Obstructive Pulmonary Disease (COPD)Tissue RegenerationChronic Diseases

Technology Platform

Patented Small Mobile Stem (SMS) cell platform producing unique, scalable, allogeneic adult stem cells derived from human peripheral blood, designed for off-the-shelf, systemic administration to engage regenerative pathways.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The lead COPD program addresses a massive, underserved market with high mortality.
A successful platform validation could enable rapid expansion into other large markets involving tissue degeneration, such as ARDS and chronic wounds, using the same scalable manufacturing process.

Risk Factors

High clinical risk as early-phase efficacy signals must be confirmed in larger trials.
Significant regulatory and development hurdles exist for a novel cell therapy.
As a pre-revenue private company, it faces substantial funding and dilution risk to continue operations and trials.

Competitive Landscape

SMSbiotech competes in the crowded regenerative medicine and cell therapy space, facing competition from other biotechs developing stem cell therapies for COPD and degenerative diseases. Its key differentiators are the novel blood-derived SMS cell source, claimed scalability, and off-the-shelf, systemic administration approach.

More companies in Cell & Gene Therapy →More companies in United States →